![]() ![]() Neutralizing antibodies positivity and percent inhibition declines 41% and 54% in patients ( p < 0.001) and 39.7% and 47% in controls (p < 0.001). ![]() Anti-S1/S2 IgG positivity and titers reduce to 23.8% and 38% in patients ( p < 0.001) during the six-month follow up and 20% and 51% in controls ( p < 0.001), respectively. Secondary outcomes are presence of neutralizing antibodies, percent inhibition by neutralizing, geometric mean titers and cumulative incident cases at 6 months after 2nd dose. The primary outcome is the presence of anti-S1/S2 SARS-CoV-2 IgG at 6 months compared to 6 weeks after 2nd vaccine dose for decay evaluation. Here we assess anti-SARS-CoV-2 immunogenicity decay and incident cases six months after the 2 nd dose of Sinovac-CoronaVac inactivated vaccine (D210) in 828 autoimmune rheumatic diseases patients compared with 207 age/sex-balanced control individuals. The determination of durability and vaccine-associated protection is essential for booster doses strategies, however data on the stability of SARS-CoV-2 immunity are scarce. Nature Communications volume 13, Article number: 5801 ( 2022) Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |